Advertisement
ABUS vs ARRY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and ARRY is a Hold.
ABUS's RSI Oscillator remains in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 63 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
ABUS moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABUS crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for ABUS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.971) is normal, around the industry mean (3.051). P/E Ratio (4.911) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARRY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARRY turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 38 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ARRY as a result. In 70 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +36.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.536) is normal, around the industry mean (2.612). P/E Ratio (-4.833) is within average values for comparable stocks, (5.606). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ARRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
ABUS | ARRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 15 | 100 | |
PRICE GROWTH RATING 1..100 | 71 | 81 | |
P/E GROWTH RATING 1..100 | 55 | 22 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (11) in the Biotechnology industry is significantly better than the same rating for ABUS (77). This means that ARRY’s stock grew significantly faster than ABUS’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ABUS (100). This means that ARRY’s stock grew similarly to ABUS’s over the last 12 months.
ABUS's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for ARRY (100). This means that ABUS’s stock grew significantly faster than ARRY’s over the last 12 months.
ABUS's Price Growth Rating (71) in the Biotechnology industry is in the same range as ARRY (81). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for ABUS (55). This means that ARRY’s stock grew somewhat faster than ABUS’s over the last 12 months.
| ABUS | ARRY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 80% |
| Advances ODDS (%) | 8 days ago 73% | 2 days ago 76% |
| Declines ODDS (%) | 2 days ago 76% | 10 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABUS’s FA Score shows that 1 FA rating(s) are green while ARRY’s FA Score has 2 green FA rating(s).
- ABUS’s FA Score: 1 green, 4 red.
- ARRY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABUS’s TA Score shows that 4 TA indicator(s) are bullish while ARRY’s TA Score has 4 bullish TA indicator(s).
- ABUS’s TA Score: 4 bullish, 6 bearish.
- ARRY’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABUS (@Biotechnology) experienced а -9.56% price change this week, while ARRY (@Alternative Power Generation) price change was +36.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.67%. For the same industry, the average monthly price growth was -11.29%, and the average quarterly price growth was -16.55%.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was +12.53%. For the same industry, the average monthly price growth was +2.35%, and the average quarterly price growth was -39.37%.
Reported Earning Dates
ABUS is expected to report earnings on Nov 12, 2026.
ARRY is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-3.67% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Alternative Power Generation (+12.53% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
Advertisement